Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 21350763)

  • 1. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles.
    Lee AL; Wang Y; Pervaiz S; Fan W; Yang YY
    Macromol Biosci; 2011 Feb; 11(2):296-307. PubMed ID: 21154473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
    Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
    Wiradharma N; Tong YW; Yang YY
    Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
    Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
    Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
    Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
    Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
    Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand.
    Na SJ; Chae SY; Lee S; Park K; Kim K; Park JH; Kwon IC; Jeong SY; Lee KC
    Int J Pharm; 2008 Nov; 363(1-2):149-54. PubMed ID: 18694811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
    Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
    Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
    Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
    J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
    Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
    Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
    Sun J; Fu ZM; Fang CQ; Li JH
    Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.